Difference between revisions of "Part:BBa K4165156"
Omnia Alaa11 (Talk | contribs) |
|||
(7 intermediate revisions by 3 users not shown) | |||
Line 3: | Line 3: | ||
<partinfo>BBa_K4165156 short</partinfo> | <partinfo>BBa_K4165156 short</partinfo> | ||
− | + | A synthetic peptide that is used for targeting misfolded tau protein (BBa_K4165009) as it binds to PHF6 of tau fibrils. | |
===Usage and Biology=== | ===Usage and Biology=== | ||
− | The amino acid sequence of the MM2 peptide is LTPHKHHKHLHA | + | The amino acid sequence of the MM2 peptide is LTPHKHHKHLHA. MM2 can reduce tau aggregates of full-length tau aggregates but not PHF* or PHF (VQIINK and VQIVYK respectively). |
− | + | ||
− | <span class='h3bb'>Sequence and Features</span> | + | <span class='h3bb'> <p style=" font-weight: bold; font-size:17px;"> Sequence and Features</p> </span> |
<partinfo>BBa_K4165156 SequenceAndFeatures</partinfo> | <partinfo>BBa_K4165156 SequenceAndFeatures</partinfo> | ||
Line 21: | Line 21: | ||
<html> | <html> | ||
− | <p><img src="https://static.igem.wiki/teams/4165/wiki/parts-registry/mm2.png" style="margin-left:200px;" alt="" width=" | + | <p><img src="https://static.igem.wiki/teams/4165/wiki/parts-registry/mm2.png" style="margin-left:200px;" alt="" width="500" /></p> |
</html> | </html> | ||
+ | |||
Figure 1.: Predicted 3D structure of Synthetic peptide MM2. | Figure 1.: Predicted 3D structure of Synthetic peptide MM2. | ||
Line 31: | Line 32: | ||
<html> | <html> | ||
− | <p><img src="https://static.igem.wiki/teams/4165/wiki/parts-registry/mm2-qa.png" style="margin-left: | + | <p><img src="https://static.igem.wiki/teams/4165/wiki/parts-registry/mm2-qa.png" style="margin-left:50px;" alt="" width="800" /></p> |
</html> | </html> | ||
− | + | <!-- --> | |
===References=== | ===References=== | ||
1. Malhis, M. (2021). Selection and characterization of D-enantiomeric peptides for the investigation of options for therapy and diagnosis of Alzheimer's disease . University of Bayreuth (Germany). | 1. Malhis, M. (2021). Selection and characterization of D-enantiomeric peptides for the investigation of options for therapy and diagnosis of Alzheimer's disease . University of Bayreuth (Germany). |
Latest revision as of 13:32, 13 October 2022
MM2 Peptide
A synthetic peptide that is used for targeting misfolded tau protein (BBa_K4165009) as it binds to PHF6 of tau fibrils.
Usage and Biology
The amino acid sequence of the MM2 peptide is LTPHKHHKHLHA. MM2 can reduce tau aggregates of full-length tau aggregates but not PHF* or PHF (VQIINK and VQIVYK respectively).
Sequence and Features
Assembly Compatibility:
- 10COMPATIBLE WITH RFC[10]
- 12COMPATIBLE WITH RFC[12]
- 21COMPATIBLE WITH RFC[21]
- 23COMPATIBLE WITH RFC[23]
- 25COMPATIBLE WITH RFC[25]
- 1000COMPATIBLE WITH RFC[1000]
Dry Lab
Modeling
MM2 is modeled by AlphaFold2, ITASSER and TrRosetta, best model obtained from TrRosetta.
Figure 1.: Predicted 3D structure of Synthetic peptide MM2.
Table 1: Quality assessment parameters of MM2 model.
References
1. Malhis, M. (2021). Selection and characterization of D-enantiomeric peptides for the investigation of options for therapy and diagnosis of Alzheimer's disease . University of Bayreuth (Germany).